Search Medical Condition
Please enter condition
Please choose location from dropdown
Clear Trial Filters
 

Trieste, Italy Clinical Trials

A listing of Trieste, Italy clinical trials actively recruiting patients volunteers.

RESULTS

Found (14) clinical trials

High Risk Neuroblastoma Study 1.7 of SIOP-Europe (SIOPEN)

In this protocol the term high-risk neuroblastoma refers to children with either disseminated disease (INSS stage 4: about 40 to 50% of all neuroblastoma) over the age of one or INSS stage 2 and 3 disease with amplification of the MycN proto-oncogene Between 10% and 20% of children with stage ...

Phase

0.0 miles

Learn More »

European Low and Intermediate Risk Neuroblastoma Protocol

LOW RISK STUDY The low risk group of patients includes NB patients without MYCN amplification with or without life threatening symptoms in the following clinical situations: Children aged 18 months with localised neuroblastoma associated with image defined risk factors precluding upfront surgery (stage INRG L2). Children aged 12 months with ...

Phase

0.0 miles

Learn More »

Safety and Efficacy Study of PG324 (Netarsudil/Latanoprost 0.02% / 0.005%) Ophthalmic Solution Compared to GANFORT Ophthalmic Solution in Open Angle Glaucoma or Ocular Hypertension

The study is intended to test the effectiveness and safety of Netarsudil / Latanoprost 0.02% / 0.005% Ophthalmic Solution, relative to GANFORT for lowering of intraocular pressure (IOP) in patients with elevated intraocular pressure

Phase

0.0 miles

Learn More »

Study Comparing Bevacizumab + Erlotinib vs Erlotinib Alone as First Line Treatment of Patients With EGFR Mutated Advanced Non Squamous Non Small Cell Lung Cancer

The co-primary objectives are to assess investigator-assess, and blinded independent centrally-reviewed progression-free survival .

Phase

0.0 miles

Learn More »

Adjuvant Treatment for High-risk Triple Negative Breast Cancer Patients With the Anti-PD-l1 Antibody Avelumab

to determine whether 1 year of adjuvant Avelumab improves disease-free survival (DFS) compared to observation in patients with high-risk primary triple negative breast cancer (all comers, unselected for PD-L1 status) who have completed treatment with curative intent including surgery of the primary tumor, neo- or adjuvant chemotherapy, and (if indicated) ...

Phase

0.0 miles

Learn More »

Thalidomide Versus Infliximab in New Onset Crohn's Disease With Poor Prognostic Factors

Crohn's disease (CD) is a life-long inflammatory bowel disease disease with an unknown pathogenesis. The ultimate goal of therapy is to modify the natural history of CD thus reducing complications. Thalidomide is a small molecule with immunomodulatory and anti-angiogenetic properties. It is currently approved for the treatment of erythema nodosum ...

Phase

0.71 miles

Learn More »

EMPagliflozin outcomE tRial in Patients With chrOnic heaRt Failure With Preserved Ejection Fraction (EMPEROR-Preserved)

The aim of the study is to evaluate efficacy and safety of empagliflozin versus placebo on top of guideline-directed medical therapy in patients with heart failure with preserved ejection fraction

Phase

1.69 miles

Learn More »

EMPagliflozin outcomE tRial in Patients With chrOnic heaRt Failure With Reduced Ejection Fraction (EMPEROR-Reduced)

The aim of the study is to investigate the safety and efficacy of empagliflozin versus placebo on top of guideline-directed medical therapy in patients with heart failure with reduced ejection fraction.

Phase

1.69 miles

Learn More »

Effects of Linagliptin on Left Ventricular Myocardial DYsfunction in Patients With Type 2 DiAbetes Mellitus and Concentric Left Ventricular Geometry

Multicentre, randomized, double blind, parallel group comparison of an DPP-4 inhibitor, linagliptin 5 mg od, versus placebo (1:1) in patients with T2DM and a documented baseline concentric LV geometry and LV systolic dysfunction. The management of glycemia will be left to the Investigator's judgment informed by clinical guidelines. The Investigator ...

Phase

2.74 miles

Learn More »

Overcoming Endocrine Resistance in Metastatic Breast Cancer

In presence of ER hypersensitivity even a small amount of ER may be sufficient for sustained growth signalling. On the other hand, ER disruption operated by fulvestrant is not complete, particularly in the initial phase of treatment. From phase III trials, indeed, The invertigators know that with the standard 250mg ...

Phase

3.05 miles

Learn More »